Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia

Reata Pharmaceuticals today announced the enrollment of the first patient in the pivotal Part 2 of the MOXIe trial to evaluate omaveloxolone in patients with Friedreich’s ataxia (FA).

"Friedreich’s ataxia is a severe, neurological disorder that profoundly impacts patients and their families. Based on the results from Part 1 of MOXIe, we are optimistic that Part 2 of the MOXIe trial could position omaveloxolone to become the first therapy approved for patients with Friedreich’s ataxia," said Warren Huff, Reata's Chief Executive Officer and President. "With the initiation of Part 2 of MOXIe, Reata has launched three pivotal programs in the last 12 months."

Read the entire Press Release HERE




Archived in
  Scientific News



Tagged in
FARA Scientific News

Privacy Policy      Service Terms      Contact      Charity Navigator